Multi-center, phase I/II clinical trials conducted by Drilon [16] and Gainor [17] have shown that Both Selpercatinib and Pralsetinib showed good tumor response in patients with RET rearrangement positive NSCLC and significantly extended disease-free survival. This evidence concerns the gene RET and non-small cell lung carcinoma.